EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The impact of the human gut microbiome on the treatment of autoimmune disease

Renuka R Nayak iD, Diego A Orellana

Immunological Reviews · 2024

DOI: 10.1111/imr.13358 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Renuka R Nayak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, Department of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Autoimmune Diseases, Precision Medicine. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, CSRD VA, NIH Office of the Director.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune (or rheumatic) diseases are increasing in prevalence but selecting the best therapy for each patient proceeds in trial‐and‐error fashion. This strategy can lead to ineffective therapy resulting in irreversible damage and suffering; thus, there is a need to bring the promise of precision medicine to patients with autoimmune disease. While host factors partially determine the therapeutic response to immunosuppressive drugs, these are not routinely used to tailor therapy. Thus, non‐host factors likely contribute. Here, we consider the impact of the human gut microbiome in the treatment of autoimmunity. We propose that the gut microbiome can be manipulated to improve therapy and to derive greater benefit from existing therapies. We focus on the mechanisms by which the human gut microbiome impacts treatment response, provide a framework to interrogate these mechanisms, review a case study of a widely‐used anti‐rheumatic drug, and discuss challenges with studying multiple complex systems: the microbiome, the human immune system, and autoimmune disease. We consider open questions that remain in the field and speculate on the future of drug–microbiome–autoimmune disease interactions. Finally, we present a blue‐sky vision for how the microbiome can be used to bring the promise of precision medicine to patients with rheumatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeAutoimmune DiseasesPrecision MedicineHumansAnimalsAutoimmunityImmunosuppressive Agents

Stichwörter der Autor:innen

autoimmunitydrug–microbiota interactionshost–microbe interactionsmicrobiomepharmacomicrobiomics

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Rheumatology Division, Department of Medicine, University of California, San Francisco, California, USA.
  • Veterans Affairs Medical Center, San Francisco, California, USA.

ORCID-Profile: Renuka R Nayak

Förderung

  • NIAMS NIH HHS
  • CSRD VA
  • NIH Office of the Director
  • NIGMS NIH HHS
  • Arthritis National Research Foundation
  • Russell/Engleman Rheumatology Research Center
  • U.S. Department of Veterans Affairs
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Nayak, R. R., & Orellana, D. A. (2024). The impact of the human gut microbiome on the treatment of autoimmune disease. Immunological Reviews. https://doi.org/10.1111/imr.13358

Vancouver

Nayak RR, Orellana DA. The impact of the human gut microbiome on the treatment of autoimmune disease. Immunological Reviews. 2024. doi:10.1111/imr.13358

BibTeX
@article{Nayak2024,
  author = {Nayak, Renuka R and Orellana, Diego A},
  title = {The impact of the human gut microbiome on the treatment of autoimmune disease},
  journal = {Immunological Reviews},
  year = {2024},
  doi = {10.1111/imr.13358}
}
Kostenlos starten →